DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
DAYVIGO’s Promise at AAN 2024: Elevating Morning Alertness and Sleep Quality in Insomnia
DAYVIGO (lemborexant) is an orexin receptor antagonist approved for treating adult patients with insomnia, who experience challenges with sleep onset and/or maintenance. It has received approval for insomnia treatment in over 15 countries, such as Japan, the United States, Canada, Australia, and various Asian nations. DAYVIGO functions by inhibiting the activity of a neurotransmitter in the brain known as orexin, which is believed to be involved in signaling the brain to awaken. Inhibiting the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is believed…
Unveiling Boundless Horizons: Unlocking BHV-7000’s Potential in Epilepsy
Biohaven with BHV-7000 underscores unwavering commitment to neurology and to addressing unmet patient needs, by providing innovative therapeutic choices with improved tolerability for epilepsy patients. BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, presents a promising avenue, navigating the complexities often associated with existing anti-seizure medications by reducing the side effects in the central nervous system. At the recently concluded American Academy of Neurology Annual Meeting (2024) Biohaven presented abstracts elucidating the characterization of their primary candidate within the Kv7 platform, BHV-7000, as a prospective treatment for seizures. These abstracts…
Promising Efficacy and Safety of Fenebrutinib in Relapsing Multiple Sclerosis (RMS): Insights from Phase II Study FENopta
Fenebrutinib distinguishes itself from other BTK inhibitors through its unique reversible mechanism. It aims to treat relapsing and primary progressive MS. Fenebrutinib treatment resulted in decreased new lesion activity and enhanced penetration into the cerebrospinal fluid (CSF) in multiple sclerosis (MS) patients. At the American Academy of Neurology conference 2024, findings from the ongoing Phase II study FENopta (NCT05119569), highlighted the efficacy and safety of fenebrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, in treating relapsing MS. Patients receiving fenebrutinib exhibited a significant reduction in total new T1 gadolinium-enhancing (Gd+)…
-Agonist.png "Toll-like Receptors Agonist")
